

# VIVUS – Qsymia’s Launch and Ex-US Partnership = Growth Drivers

<https://marketpublishers.com/r/VAB52DEA814EN.html>

Date: July 2012

Pages: 3

Price: US\$ 140.00 (Single User License)

ID: VAB52DEA814EN

## Abstracts

Approval of Qsymia (Qnexa – combination of phentermine and topiramate) by US FDA and launch by 4Q12 ahead of rival drug, Arena/Eisai's Belviq (lorcaserin, 5-HT<sub>2C</sub> receptor agonist) should give Vivus (VVUS) the first mover advantage, as Qsymia already has a DEA controlled-substance classification while Belviq should become available by... Though Qsymia's label is similar to Belviq, the discontinuation rules for Qsymia favor VVUS – discontinuation recommended at 14-wk and 28-wk if... Qsymia offers the best efficacy amongst the approved and drugs in pipeline for treating obesity, and we expect Qsymia to achieve worldwide peak sales... For more detail, please read our report released on July 19, 2012 on VVUS, titled "Qsymia's Launch and Ex-US Partnership = Growth Drivers

## Contents

### COMPANIES MENTIONED

Vivus

## I would like to order

Product name: VIVUS – Qsymia’s Launch and Ex-US Partnership = Growth Drivers

Product link: <https://marketpublishers.com/r/VAB52DEA814EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VAB52DEA814EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970